Murray, Melissa E. http://orcid.org/0000-0001-7379-2545
Moloney, Christina M.
Kouri, Naomi
Syrjanen, Jeremy A.
Matchett, Billie J.
Rothberg, Darren M.
Tranovich, Jessica F.
Sirmans, Tiffany N. Hicks
Wiste, Heather J.
Boon, Baayla D. C.
Nguyen, Aivi T.
Reichard, R. Ross
Dickson, Dennis W.
Lowe, Val J.
Dage, Jeffrey L.
Petersen, Ronald C.
Jack, Clifford R. Jr
Knopman, David S.
Vemuri, Prashanthi
Graff-Radford, Jonathan
Mielke, Michelle M.
Article History
Received: 24 May 2022
Accepted: 26 October 2022
First Online: 27 December 2022
Declarations
:
: The Mayo Clinic and Olmsted Medical Center Institutional Review Boards approved this study. All participants provided written informed consent.
: Not applicable.
: MEM is a consultant for AVID Radiopharmaceuticals. She receives support from the NIH/NIA and State of Florida. VJL serves as consultant for Bayer Schering Pharma, Philips Molecular Imaging, Piramal Imaging, AVID Radiopharmaceuticals, Eisai Inc., and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), and the MN Partnership for Biotechnology and Medical Genomics. JLD was previously an employee and stockholder of Eli Lilly and Company. RCP serves as a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc. (DSMB), Nestle, Inc., and Eisai, Inc., receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and UpToDate. CRJ serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. DSK serves on a Data Safety Monitoring Board for the DIAN study. He served on a Data Safety monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is a site investigator in the Biogen aducanumab trials. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Roche and Alzeca Biosciences but receives no personal compensation. PV received speaker fees from Miller Medical Communications, Inc. and receives research support from the NIH. JGR serves on the editorial board for Neurology and receives research support from the NIH. MMM consulted for Biogen and Brain Protection Company and receives funding from the NIH/NIA and DOD.